EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous 
Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM) 
(RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial 
 
2021-01-11 / 07:00 
 
*Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM) 
(RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial* 
 
*Geneva, Switzerland and Radnor, Pa, USA, January 11, 2021 -* RELIEF 
THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("*Relief*" or the 
"*Company*"), NeuroRx, Inc. and the Quantum Leap Healthcare Collaborative 
("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed 
a Clinical Trial Participation Agreement for the inclusion of ZYESAMI(TM) 
(RLF-100TM: aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is 
the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing 
multiple drugs for the treatment of patients with Critical COVID-19 who are 
hospitalized or in intensive care units. ZYESAMI(TM) will be included as one 
of the first drugs targeting Respiratory Failure in critically ill COVID-19 
patients. 
 
The inclusion of ZYESAMI(TM) in the I-SPY COVID-19 Trial follows a request 
from the U.S. Department of Health and Human Services and the Department of 
Defense for investigational drugs capable of targeting the most acutely ill 
patients with COVID-19. ZYESAMI(TM) has been granted Fast Track designation 
by the U.S. Food & Drug Administration (FDA) for the treatment of Critical 
COVID-19 in patients with Respiratory Failure. 
 
In December 2020, *Dr. Robert Kadlec, HHS Assistant Secretary for 
Preparedness and Response*, issued a public statement that "Through our 
Operation Warp Speed partnership, we have worked feverishly with private 
industry to develop and make treatments available to reduce hospitalization, 
either shortening the length of stay or treating people with mild or 
moderate COVID-19 infections before they have to be hospitalized. While 
we're making significant progress, treatments to save lives of the sickest 
patients, such as patients in intensive care or on ventilators, remain an 
urgent need." 
 
I-SPY is a platform clinical trial that uses a similar protocol as a 
traditional clinical trial, but that compares multiple investigational 
agents combined with a "backbone" of the standard of care. The trial is 
designed to rapidly identify those agents that have a large impact on 
reducing disease severity, including reduced mortality, reducing or avoiding 
time on ventilation and other longer-term comorbidities. Patients receive 
one of several products being studied and the results then are compared to 
the current standard of care. 
 
"We are excited to be collaborating with NeuroRx, an innovative company 
developing agents that have the potential to significantly impact the time 
to recovery and mortality in these severely ill COVID-19 patients," states 
*Dr. Laura Esserman, one of the lead investigators of the I-SPY COVID-19 
Trial*. "Our adaptive platform trial setting is the ideal type of study to 
follow a trial that has findings suggesting agent effectiveness. We have the 
ability to independently verify impact, as well as test different modes of 
delivery in a pandemic timeframe." 
 
"We at NeuroRx, together with our partners at Relief, are honored to have 
been selected by Quantum Leap for inclusion in the I-SPY trials platform. 
This will enable us to gather data on the use of inhaled aviptadil in the 
treatment of Critical COVID-19, as a complement to data on the use of 
intravenous aviptadil in the phase 2b/3 trial we are just concluding. We 
also hope to demonstrate in a second phase 2b/3 trial that aviptadil can be 
given in a more convenient mode of administration and show benefit in 
patients who are able to self-administer inhaled medications," said 
*Jonathan C. Javitt, MD, MPH, CEO and Chairman of NeuroRx*. 
 
### 
 
*ABOUT ZYESAMI(TM) (PREVIOUSLY RLF-100(TM): AVIPTADIL)* 
 
*ZYESAMI(TM) (RLF-100(TM): AVIPTADIL) IS A FORMULATION OF VASOACTIVE 
INTESTINAL POLYPEPTIDE (VIP) *that was developed based on Prof. Sami Said's 
original work at Stony Brook University, for which Stony Brook was awarded 
an FDA Orphan Drug Designation in 2001. VIP is known to be highly 
concentrated in the lungs, where it inhibits coronavirus replication, blocks 
the formation of inflammatory cytokines, prevents cell death, and 
upregulates the production of surfactant. FDA has granted IND authorization 
for intravenous and inhaled delivery of aviptadil for the treatment of 
COVID-19 and awarded Fast Track designation. ZYESAMI(TM) is being 
investigated in two placebo-controlled US phase 2b/3 clinical trials in 
respiratory deficiency due to COVID-19. Since July 2020, more than 300 
patients with Critical COVID-19 and Respiratory Failure have been treated 
with RLF-100(TM) between the two FDA-cleared protocols (randomized and 
expanded access). Information on the RLF-100(TM) Expanded Access Program can 
be found at https://www.neurorxpharma.com/our-services/rlf-100 [1]. 
 
*ABOUT RELIEF* 
 
Relief focuses primarily on clinical-stage programs based on molecules of 
natural origin (peptides and proteins) with a history of clinical testing 
and use in human patients or a strong scientific rationale. Currently, 
Relief is concentrating its efforts on developing new treatments for 
respiratory disease indications. Its lead drug candidate RLF-100TM 
(aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 
clinical trials in respiratory deficiency due to COVID-19. Relief also holds 
a patent issued in the United States and various other countries covering 
potential formulations of RLF-100TM. 
 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the 
symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. 
www.relieftherapeutics.com [2] 
 
Follow us on *LinkedIn [3].* 
 
*ABOUT NEURORX, INC.* 
 
NeuroRx draws upon more than 100 years of collective drug development 
experience and by former senior executives of AstraZeneca, Eli Lilly, 
Novartis, Pfizer, and PPD. In addition to its work on ZYESAMI(TM), which has 
been awarded FDA Fast Track designation (previously RLF-100(TM): Aviptadil), 
NeuroRx has been awarded Breakthrough Therapy Designation and a Special 
Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is 
currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. 
Javitt, MD, MPH, who has served as a health advisor to four Presidential 
administrations and worked on paradigm-changing drug development projects 
for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together 
with Robert Besthof, MIM, who served as the Global Vice President 
(Commercial) for Pfizer's Neuroscience and Pain Division. The Company has 
recently announced a plan to merge with Big Rock Partners Acquisition Corp 
(NASDAQ:BRPA) ("Big Rock"), following which it is expected to trade on the 
NASDAQ as NRXP. 
 
*ABOUT QUANTUM LEAP HEALTHCARE COLLABORATIVE * 
 
Quantum Leap Healthcare Collaborative is a 501(C)(3) charitable organization 
established in 2005 as a collaboration between medical researchers at 
University of California, San Francisco, academic medical sites and clinical 
researchers (nationwide), the pharma industry and healthcare technology 
leaders. Its mission is to integrate high-impact research with clinical 
processes and systems technology, resulting in improved data management and 
information systems, greater access to clinical trial matching and 
sponsorship, and greater benefit to providers, patients and researchers. Its 
goal is to improve and save lives. Quantum Leap provides sponsorship as well 
as operational, financial, and regulatory oversight to the I-SPY Trials. For 
more information, visit www.QuantumLeapHealth.org. 
 
*ABOUT BIG ROCK PARTNERS ACQUISITION CORP. * 
 
Big Rock Partners Acquisition Corp. is a blank check company formed for the 
purpose of entering into a merger, stock exchange, asset acquisition, stock 
purchase, recapitalization, reorganization, or other similar business 
combination with one or more businesses or entities. Big Rock's management 
team includes Richard Ackerman, Chairman, President, and Chief Executive 
Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, 
Corporate Secretary and Director. Big Rock's common stock, units, rights and 
warrants are quoted on the Nasdaq Capital Market under the ticker symbols 
BRPA, BRPAU, BRPAR and BRPAW, respectively. 
 
*ADDITIONAL INFORMATION AND WHERE TO FIND IT* 
 
This document relates to a proposed transaction between NeuroRx and Big 
Rock. This document does not constitute an offer to sell or exchange, or the 
solicitation of an offer to buy or exchange, any securities, nor shall there 
be any sale of securities in any jurisdiction in which such offer, sale or 
exchange would be unlawful prior to registration or qualification under the 
securities laws of any such jurisdiction. Big Rock intends to file a 
registration statement on Form S-4 ("Registration Statement"), which will 
include a proxy statement for the solicitation of Big Rock shareholder 
approval, a prospectus for the offer and sale of Big Rock securities in the 
transaction and a consent solicitation statement of NeuroRx, and other 
relevant documents with the Securities and Exchange Commission ("SEC"). The 
proxy statement/consent solicitation statement/prospectus will be mailed to 
stockholders of Big Rock and NeuroRx as of a record date to be established 
for voting on the proposed business combination. INVESTORS AND SECURITY 
HOLDERS OF BIG ROCK AND NEURORX ARE URGED TO READ THE REGISTRATION 
STATEMENT, PROXY STATEMENT/CONSENT SOLICITATION STATEMENT/PROSPECTUS AND 
OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN 
THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN 
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security 
holders will be able to obtain free copies of the registration statement, 
proxy statement, prospectus and other documents containing important

(MORE TO FOLLOW) Dow Jones Newswires

January 11, 2021 01:00 ET (06:00 GMT)